Camlin Fine
Camlin Fine Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Blends business expected to grow approximately 20% annually over the next 2-3 years, with EBITDA margins moving towards high teens and potentially nearing 20% as the business matures. Blends business expected to grow around 20% annually over the next 2-3 years, with EBITDA margins in the high teens advancing towards 20%. - Total blended business revenue to rise from INR878 crores currently with a 20% CAGR for the next 2 years. - Vanillin plant utilization targeted to reach 100% within 2 years, driving volume growth. - Aroma business revenue at INR176 crores in FY'25 expected to ramp up further, supported by anti-dumping duties in the U.S.
From Camlin Fine's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Blends business expected to grow approximately 20% annually over the next 2-3 years, with EBITDA margins moving towards high teens and potentially nearing 20% as the business matures.
- Aroma business to continue momentum with anticipated revenue increase fueled by anti-dumping duties in the U.S. and EU, supporting price rises.
- Vanillin business expected to ramp up to 100% capacity utilization over the next 2 years, with volume growth anticipated in U.S. and European markets due to anti-dumping duties favoring domestic producers.
- Total core business has grown about 15% year-on-year, with healthy volume growth in blends, especially in North America and India.
2 more points from Camlin Fine's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Camlin Fine said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Currently, Camlin Fine Sciences is not planning any significant capital expenditure.
- The focus is on optimizing and "sweating" the vanillin plant rather than new large investments.
- Only maintenance capex and some minor debottlenecking activities are anticipated.
2 more points from Camlin Fine's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Camlin Fine said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Nirmal Momaya mentioned there are very good conversations and contracts being negotiated in the pipeline, particularly related to aroma and blend businesses.
- For vanillin, major players including Solvay and Camlin are actively pursuing contract negotiations in the U.S. and Europe.
- The anti-dumping duty approvals in the U.S. and Europe are expected to result in volume growth over the next 3 to 4 quarters.
- No specific quantitative order book or pending orders figures were disclosed.
- The management indicated cautious volume commitments due to existing customer inventories and ongoing price negotiations.
2 more points from Camlin Fine's call on order book
Pro opens every point from 15K+ earnings calls
Camlin Fine — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹425 Cr, net profit ₹86 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Camlin Fine's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Atul (Q4 FY25)
Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…
- Vidhi Specialty (Q4 FY25)
109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Chemcon Speciality Chemicals Ltd (Q4 FY25)
54.9 Crs, down 8% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Valiant Organics (Q4 FY25)
Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…
Arthneeti Pro · Annual
Camlin Fine and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Camlin Fine Q4 FY25 results?
Blends business expected to grow approximately 20% annually over the next 2-3 years, with EBITDA margins moving towards high teens and potentially nearing 20% as the business matures. Blends business expected to grow around 20% annually over the next 2-3 years, with EBITDA margins in the high teens advancing towards 20%. - Total blended business revenue to rise from INR878 crores currently with a 20% CAGR for the next 2 years. - Vanillin plant utilization targeted to reach 100% within 2 years, driving volume growth. - Aroma business revenue at INR176 crores in FY'25 expected to ramp up further, supported by anti-dumping duties in the U.S.
What is Camlin Fine share price analysis?
Camlin Fine currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,993 Cr. Investors should review the full earnings analysis for detailed insights.
Is Camlin Fine planning capital expenditure?
Currently, Camlin Fine Sciences is not planning any significant capital expenditure.
Keep Camlin Fine on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.